QIAGEN expands access to state-of-the-art HPV screening in China through co-marketing agreement with KingMed Diagnostics
Agreement will make HPV testing more widely available throughout China
13-Mar-2012
- China
QIAGEN N.V. announced that it will expand access to its digene HPV Test across China through a co-marketing agreement with KingMed Diagnostics. Through the agreement, KingMed Diagnostics will function as a centralized lab, allowing smaller hospitals and those in less-populated areas to offer the digene HPV Test and send samples to KingMed Diagnostics for processing and analysis. The agreement is an additional milestone for QIAGEN’s molecular diagnostics franchise in China and its focus on driving growth in emerging markets. The digene HPV Test was first registered in China in 2000 and is now widely available in many of the country’s top-tier hospitals and private labs.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Thermo Fisher Scientific Scientist Dr. Alexander Makarov Receives Inaugural HUPO Science and Technology Award
Healthcare is up for a Revolution with the Rise of Personal Genomic Tests - Frost & Sullivan finds that direct to consumer genomics, which were close to absent a decade ago, are currently thriving
Varian, Inc. Named 2004 Analytical Instrumentation Company of the Year by Frost & Sullivan
Sticky stuff: Jacobs researchers reveal the sweet secret of caramel
Affibody to start clinical development of a approach for the diagnosis of cancer - Swedish MPA gives go ahead for the clinical trial of Affibody's molecular imaging agent designed to improve the diagnosis of HER2-positive breast cancer.
Galapagos wins 2011 Scrip Award for Biotech Company of the Year
Drug Discovery Companies Focus on Strong Product Line to Offset R&D Budget Slowdown
